BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma

Therapeutic Exploitation of Tumor Cell Defects in Homologous Recombination

(2012) Simon Powell et al.   Anti-Cancer Agents in Medicinal Chemistry

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

(2011) A Mukhopadhyay et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

(2010) Christopher G. Przybycin et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity

(2010) D. J. Gallagher et al.   ANNALS OF ONCOLOGY

SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors

(2010) Rodrigo Goya et al.   BIOINFORMATICS

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

(2010) Pierfrancesco Tassone et al.   CANCER BIOLOGY & THERAPY

Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy

(2010) Angiolo Gadducci et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

(2010) Helen J. Mackay et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

(2010) Bryan T.J. Hennessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas

(2010) Martin Köbel et al.   JOURNAL OF PATHOLOGY

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

Intraepithelial T cells and tumor proliferation

(2009) Sarah F. Adams et al.   CANCER

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

Dramatic Response to Platinum in a Patient with Cancer with a Germline BRCA2 Mutation

(2009) R. Moule et al.   CLINICAL ONCOLOGY

Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications

(2009) Martin Köbel et al.   GYNECOLOGIC ONCOLOGY

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

(2009) Sohrab P. Shah et al.   NATURE

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

(2009) Katy Milne et al.   PLoS One

Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment

(2008) Ashok R. Venkitaraman   Annual Review of Pathology-Mechanisms of Disease

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

(2008) Ninke Leffers et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

(2008) L. Y. Han et al.   CLINICAL CANCER RESEARCH

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

(2008) C. Blake Gilks et al.   HUMAN PATHOLOGY

The impact of T-cell immunity on ovarian cancer outcomes

(2008) Brad H. Nelson   IMMUNOLOGICAL REVIEWS

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

(2008) Blaise Clarke et al.   MODERN PATHOLOGY

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

(2008) Martin Köbel et al.   PLOS MEDICINE

Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma

(2007) Dennis S. Chi et al.   GYNECOLOGIC ONCOLOGY